RedHill Biopharma Ltd.
RDHLNasdaq
$0.71
↓ -3.6%Jul 17 close · end-of-day
Price
1Y↓ -63.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
RedHill Biopharma Ltd. primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections.
- CEO
- Dror Ben-Asher
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 210
- Website
- redhillbio.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 22, 2026
Jun 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Raday Gilead· Chief Operating Officer | Sale | 14,130,000 | $0.00 | $1,413.00 | filing |
| 2026-04-06 | Raday Gilead· Chief Operating Officer | Sale | 15,740,000 | $0.00 | $1,574.00 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.